Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)

20 novembre 2020 mis à jour par: Centre Hospitalier Annecy Genevois

Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Aperçu de l'étude

Statut

Complété

Description détaillée

Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.

The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.

For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.

The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.

As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.

Type d'étude

Observationnel

Inscription (Réel)

320

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Boulogne Billancourt, France
        • Hopital Ambroise Pare Ap-Hp
      • Brest, France
        • Centre Hospitalier Universitaire Brest
      • Chambéry, France
        • Centre Hospitalier Metropole Savoie
      • Créteil, France
        • Centre Hospitalier Intercommunal de Créteil
      • Grenoble, France
        • Centre Hospitalier Universitaire Grenoble Alpes
      • Le Chesnay, France
        • Centre Hospitalier de Versailles André Mignot
      • Lille, France
        • Centre Hospitalier Universitaire de Lille
      • Lyon, France
        • Hospices Civils de Lyon
      • Lyon, France
        • Centre Leon Berard Lyon
      • Mantes-la-Jolie, France
        • Centre Hospitalier François Quesnay
      • Metz-Tessy, France, 74374
        • Centre Hospitalier Annecy Genevois
      • Paris, France
        • Institut Curie
      • Saint-Cloud, France
        • Institut Curie Saint Cloud
      • Saint-Étienne, France
        • Institut de Cancérologie Lucien Neuwirth
      • Suresnes, France
        • Hôpital Foch

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

The study will include all eligible patients who started paclitaxel-bevacizumab between January 1, 2010 and May 1, 2018. The number of patients is estimated to be approximately 200.

La description

Inclusion Criteria:

  • At least 18 years old;
  • Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
  • Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
  • Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
  • Alive patients not opposed to the use of their data

Exclusion Criteria:

  • Patient under guardianship or curatorship at the date of the study ;
  • Patients alive at the time of the study who are opposed to the use of their data
  • Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival
Délai: Up to 12 months
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
Up to 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Drugs administration dosage description
Délai: Up to 12 months
Description of the different monthly drug administration regimens
Up to 12 months
Objective response rate and control rate
Délai: Up to 12 months
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
Up to 12 months
Overall survival Rate
Délai: Up to 12 months
Overall survival, assessed on the whole population
Up to 12 months
Objective Response Rate
Délai: Up to 12 months

Objective Response Rate in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Progression-Free Survival Rate
Délai: Up to 12 months

Progression-Free Survival in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Disease Control Rate
Délai: Up to 12 months

Disease Control in the following subgroups:

  • patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Overall Survival Rate
Délai: Up to 12 months

Overall Survival in the following subgroups:

  • Patients treated after immunotherapy and especially immediately after immunotherapy;
  • Patients with an oncogenic EGFR or ALK addiction pathway;
  • Patients previously treated with taxanes;
  • Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Frequency of safety events
Délai: Up to 12 months
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
Up to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Chantal Decroisette, CH Annecy Genevois

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 octobre 2019

Achèvement primaire (Réel)

5 juin 2020

Achèvement de l'étude (Réel)

5 juin 2020

Dates d'inscription aux études

Première soumission

9 novembre 2020

Première soumission répondant aux critères de contrôle qualité

20 novembre 2020

Première publication (Réel)

23 novembre 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 novembre 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 novembre 2020

Dernière vérification

1 novembre 2020

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner